The Lynx Group

Stephan Stilgenbauer, MD

Authored Items

Venetoclax: Strong Showing in CLL

February 2016, Vol. 5, No. 1 - ASH 2015, ASH Highlights

Venetoclax, an oral, investigational, small molecule Bcl-2 inhibitor, achieved excellent and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (RR CLL). All patients in the trial harbored a 17p deletion, signaling poor prognosis.In a pivotal phase 2 trial reported at the meeting, nearly 80% of patients with high-risk RR [ Read More ]

Sign me up!